A Phase 2/3 interventional study of Exercise, nutritional and pharmaceutical counseling in Chagas Disease and Chagas Cardiomyopathy, sponsored by Evandro Chagas National Institute of Infectious Disease. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-05.
Sponsored by Evandro Chagas National Institute of Infectious Disease · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Chagas Cardiomyopathy with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Chagas Cardiomyopathy · Brazil.
Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2013, is the only one in phase 2/3, and was the 8th registered.
17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.
Browse Chagas Cardiomyopathy studies →2 of the 14 studies in Chagas Cardiomyopathy with a site in Brazil are open now. Recruiting first, the newest first:
InCor Heart Institute · Sites in Brazil
Ages 18–75
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 2 Chagas Cardiomyopathy studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 4 · Phase 4 2
First in 1995; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 45 across 13 interventional studies indexed under Chagas Cardiomyopathy.
Median enrollment 42 across the 11 interventional studies, 100 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 9 most frequent:
Evandro Chagas National Institute of Infectious Disease is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Evandro Chagas National Institute of Infectious Disease has 2 studies filed under Chagas Cardiomyopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Due to the lack of information in the literature about the role of cardiac rehabilitation on Chagas heart failure, the aim of the present study was to evaluate the effects of a cardiac exercise program on functional capacity, cardiac function, respiratory muscle strength, body composition, biomarkers and quality of life among Chagas heart failure patients.
The present study consisted in a pre/post single-arm intervention study conducted at the Evandro Chagas National Institute of Infectious Disease (INI), located on Rio de Janeiro, Brazil. INI is a national reference center for treatment and research in infectious diseases and tropical medicine in Brazil, which follows a large cohort of patients with Chagas disease, all of them diagnosed by two simultaneously positive serological tests (enzyme-linked immunosorbent assay and indirect immunofluorescence). Patients included in the study were submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during an 8-month period. Nutritional and pharmaceutical counseling were also monthly provided during the follow-up and consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.Patients included in the study were followed during an 8-month period in which evaluations of functional capacity (maximal progressive cardiopulmonary exercise test), muscle respiratory strength (manovacuometry) and body composition (anthropometry and skinfolds) were performed at baseline, after four months and at the end of follow-up. Assessments of cardiac function (bidimensional echocardiography), biomarkers (lipid profile, glucose and glycated hemoglobin) and quality of life (Minnesota Living with Heart Failure questionnaire) were taken at baseline and after eight months of follow-up.
17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.
This study's enrollment of 12 is below the median of 45 across 13 interventional studies indexed under Chagas Cardiomyopathy.
Browse Chagas Cardiomyopathy studies →Evandro Chagas National Institute of Infectious Disease is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Compared within Chagas Cardiomyopathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Chagas Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Physical exercise intervention * Nutritional counseling * Pharmaceutical counseling
Behavioral: Exercise, nutritional and pharmaceutical counseling
Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
Functional Capacity (VO2 max)
VO2 max (ml/kg/min)
Time frame: Change from baseline at 4 and 8 months
Muscle respiratory strength (maximal inspiratory pressure and maximal expiratory pressure)
Maximal inspiratory pressure and maximal expiratory pressure (cm H2O)
Time frame: Change from baseline at 4 and 8 months
Body composition (body fat percentage)
Body fat percentage (%)
Time frame: Change from baseline at 4 and 8 months
Cardiac function (mainly ejection fraction)
Ejection fraction (%)
Time frame: Change from baseline at 8 months
Biomarkers (lipid profile and glucose)
Total cholesterol, Triacylglycerol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol (mg/dl) and glucose (mg/dl)
Time frame: Change from baseline at 8 months
Biomarkers (glycated hemoglobin)
Glycated hemoglobin (%)
Time frame: Change from baseline at 8 months
Quality of life by Minnesota Living with heart failure questionnaire (MLHFQ)
MLHFQ Score ranging from 0 to 105
Time frame: Change from baseline at 8 months
Anthropometry
Body weight (kg)
Time frame: Change from baseline at 4 and 8 months
Anthropometry
Waist and hip circumference (cm)
Time frame: Change from baseline at 4 and 8 months
The record gives a start of May 2013, a primary completion of Jan 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evandro Chagas National Institute of Infectious Disease